Herpes zoster or 'shingles' is a localised, painful, vesicular skin rash resulting from reactivation of the same virus (the varicella-zoster virus) that causes chickenpox earlier in life. Shingles can affect any part of the body but the rash classically takes the shape of a belt or band in the thoracic or lumbar region. Although usually self-limiting, shingles can lead to post-herpetic neuralgia (PHN), a chronic neuropathic pain syndrome, and other complications. About 20-30% of people will have shingles in their lifetime, most after the age of 50 years. Older people (particularly those aged over 70 years) are also more likely to have shingles complicated by PHN.
Who should be vaccinated There is one zoster vaccine that is registered for use in people aged 50 years and over as a single dose. It is recommended for adults aged 60 years and over who are not immunocompromised. Zoster vaccine is funded under the National Immunisation Program for persons aged 70 years, with catch-up for those aged 71-79 years also funded until October 2021.
Who should not be vaccinated People who are immunocompromised due to disease or medication, pregnant women, and those who have previously had anaphylaxis to any VZV-containing vaccine or its components should not receive the zoster vaccine.
Vaccine The vaccine contains live attenuated varicella-zoster virus. The amount of virus in the zoster vaccine is approximately 14 times greater than in varicella (chickenpox) vaccines. Vaccination of people aged 70-79 years is estimated to prevent about 41% of the cases of shingles and two-thirds of post-herpetic neuralgia cases in that population. In vaccinated people in whom an episode of shingles occurs, the pain, severity and duration is reduced by 50%. Protection from vaccination tends to decline with older age at vaccination and the time since vaccination. However, a booster dose is not currently recommended. Medical therapy (such as analgesics and antivirals) should still be considered for treatment of shingles, regardless of the patient's immunisation status. The vaccine is safe and well tolerated among immunocompetent individuals aged 50 years and over in clinical trials and post-licensure studies. Mild reactions at the injection site, such as pain, swelling and redness, are likely to occur in approximately 50% of vaccine recipients.